About: Α5IA

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

α5IA (LS-193,268) is a nootropic drug invented in 2004 by a team working for Merck, Sharp and Dohme, which acts as a subtype-selective inverse agonist at the benzodiazepine binding site on the GABAA receptor. It binds to the α1, α2, α3 and α5 subtypes.

Property	Value
dbo:abstract	α5IA (LS-193,268) is a nootropic drug invented in 2004 by a team working for Merck, Sharp and Dohme, which acts as a subtype-selective inverse agonist at the benzodiazepine binding site on the GABAA receptor. It binds to the α1, α2, α3 and α5 subtypes. (en)
dbo:casNumber	215874-86-5
dbo:fdaUniiCode	1M7NI1A92L
dbo:pubchem	6918451
dbo:thumbnail	wiki-commons:Special:FilePath/Alpha5IA.svg?width=300
dbo:wikiPageID	19165927 (xsd:integer)
dbo:wikiPageLength	4408 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1064902559 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Benzodiazepine dbc:GABAA_receptor_negative_allosteric_modulators dbc:Triazoles dbr:GABRA3 dbc:Aromatic_ethers dbr:GABAA_receptor dbr:GABAA_receptor_negative_allosteric_modulator dbr:GABRA2 dbr:GABRA5 dbr:Local_field_potential dbr:Nootropic dbr:Receptor_(biochemistry) dbr:Inverse_agonist dbc:Isoxazoles dbc:Phthalazines dbr:Merck_&_Co. dbr:Sharp_waves_and_ripples dbr:GABRA1
dbp:atcPrefix	None (en)
dbp:c	17 (xsd:integer)
dbp:casNumber	215874 (xsd:integer)
dbp:chemspiderid	5293648 (xsd:integer)
dbp:drugName	α5IA (en)
dbp:h	14 (xsd:integer)
dbp:iupacName	3 (xsd:integer)
dbp:n	8 (xsd:integer)
dbp:o	2 (xsd:integer)
dbp:pubchem	6918451 (xsd:integer)
dbp:smiles	CC1=CCC2=NN=C3N2N=COCC5=CNC (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	NZMJFRXKGUCYNP-UHFFFAOYSA-N (en)
dbp:synonyms	LS-193,268 (en)
dbp:unii	1 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:GABA_receptor_modulators dbt:Reflist dbt:Short_description dbt:Fdacite dbt:Lowercase
dcterms:subject	dbc:GABAA_receptor_negative_allosteric_modulators dbc:Triazoles dbc:Aromatic_ethers dbc:Isoxazoles dbc:Phthalazines
gold:hypernym	dbr:Drug
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatMolecularFormulas yago:Abstraction100002137 yago:Adversary109773245 yago:CausalAgent100007347 yago:Communication100033020 yago:Formula106816935 yago:LivingThing100004258 yago:Message106598915 yago:MolecularFormula106817173 yago:Object100002684 yago:Organism100004475 yago:Person100007846 yago:PhysicalEntity100001930 yago:WikicatGABAAntagonists yago:YagoLegalActor yago:YagoLegalActorGeo dbo:Drug yago:Statement106722453 yago:Whole100003553
rdfs:comment	α5IA (LS-193,268) is a nootropic drug invented in 2004 by a team working for Merck, Sharp and Dohme, which acts as a subtype-selective inverse agonist at the benzodiazepine binding site on the GABAA receptor. It binds to the α1, α2, α3 and α5 subtypes. (en)
rdfs:label	Α5IA (en)
owl:sameAs	freebase:Α5IA wikidata:Α5IA dbpedia-sh:Α5IA dbpedia-sr:Α5IA https://global.dbpedia.org/id/4y9eN
prov:wasDerivedFrom	wikipedia-en:Α5IA?oldid=1064902559&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Alpha5IA.svg
foaf:isPrimaryTopicOf	wikipedia-en:Α5IA
foaf:name	α5IA (en)
is dbo:wikiPageRedirects of	dbr:C17H14N8O2 dbr:LS-193,268
is dbo:wikiPageWikiLink of	dbr:C17H14N8O2 dbr:GABAA_receptor dbr:GABAA_receptor_negative_allosteric_modulator dbr:GABRA5 dbr:L-655,708 dbr:L-838,417 dbr:LS-193,268
is foaf:primaryTopic of	wikipedia-en:Α5IA